Activity of flavone acetic acid (NSC-347512) against solid tumors of mice Thomas H. CorbettMarie-Christine BisseryFrederick Valeriote Preclinical Studies Pages: 207 - 220
Effects of the new mitotic inhibitor pyrimidinsulfone NY 4137 on human cells in vitro and on colchicine binding to tubulin Mina E. Holm NygaardJohn M. DornishKjell Undheim Preclinical Studies Pages: 221 - 229
Activity of RA-700, a cyclic hexapeptide from Rubiae Radix, in the human tumor clonogenic assay Katsuhiro InoueTaketo MukaiyamaMakoto Ogawa Preclinical Studies Pages: 231 - 236
A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy Sheldon A. WeinerEarl A. SurwitFrank L. Meyskens Jr. Phase I and Pharmacology Trials Pages: 241 - 244
Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia Yei-Mei PengDavid S. AlbertsFrank L. Meyskens Jr. Phase I and Pharmacology Trials Pages: 245 - 249
Phase I clinical study of nafazatrom Gabriel N. HortobagyiNicholas E.J. PapadoupoulosJames M. Reuben Phase I and Pharmacology Trials Pages: 251 - 255
A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma Frank L. Meyskens JrEdwin M. KingsleyAnn Booth Phase II Trials Pages: 257 - 262
Oral idarubicin in non-Hodgkin's lymphomas Massimo LopezLuigi Di LauroPaola Papaldo Phase II Trials Pages: 263 - 267
Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma Theodore A. BraichSydney E. SalmonHarinder S. Garewal Phase II Trials Pages: 269 - 274
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial Howard S. HochsterMichael D. GreenFranco M. Muggia Phase II Trials Pages: 275 - 278
